J Korean Assoc Oral Maxillofac Surg.  2010 Jun;36(3):206-210. 10.5125/jkaoms.2010.36.3.206.

Consideration for treatment of bisphosphonate-related osteonecrosis of the jaw

• You KH
• Yoon KH
• Bae JH
• Park JA
• Park GC
• Shin JM
• Baik JS
• Cheong JK

• KMID: 2189949
• DOI: http://doi.org/10.5125/jkaoms.2010.36.3.206

Abstract

Bisphosphonates are widely used to treat osteoporosis, hypercalcemia of malignant tumor. Despite their clinical benefit, bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a newly documented complication to patients receiving these drugs and first recognized by Marx in 2003. Thus, consideration of prevention and needs regarding unequivocal treatment regimen have emerged. Recently, several authors emphasized reports on appropriate clinical availability of surgical approach. It serves to concern about guideline for surgical and conservative treatment modalities. So, it is the purpose of this paper to review the current literatures about treatment regimens of BRONJ.

Keyword

Bisphosphonate; Osteonecrosis; Osteoporosis

MeSH Terms

Bisphosphonate-Associated Osteonecrosis of the Jaw
Diphosphonates
Humans
Hypercalcemia
Osteonecrosis
Osteoporosis
Diphosphonates

Reference

References

1. Owens G, Jackson R, Lewiecki EM. An integrated approach: bisphosphonate management for treatment of osteoporosis. Am J Manag Care. 2007; 13(Suppl 11):S290–308.

2. Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61:1115–7.

3. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg. 2009; 67(5 Suppl 1):13–8.

4. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res. 2007; 86:1013–21.

5. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65:415–23.

6. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65:369–76.

7. The Korean Endocrine Society, the Korean Society of Bone Metabolism, the Korean Society of Osteoporosis, the Korean Association of Oral and Maxillofacial Surgeons. Bisphosphonate related osteonecrosis of the jaw (BRONJ)-position statement of Korea. J Korean Endocr Soc. 2009; 24:227–30.

8. Ohe JY, Kwon YD, Kim YG, Lee BS. Yoon BW, Choi BJ. Features of histologic and radiographic findings in bisphosphonate-related osteonecrosis of jaw-clinical review. J Korean Assoc Oral Maxillofac Surg. 2008; 34:550–4.

9. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2–12.

10. Kwon YD, Yoon BW, Walter C. Bispohspohonate, is it an emerging risk factor in oral surgery? J Korean Assoc Maxillofac Plast Reconstr Surg. 2007; 29:456–62.

11. Siddiqi A, Payne AG, Zafar S. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 108:e1–8.

12. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteonecrosis. J Oral Pathol Med. 2006; 35:155–60.

13. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonateassociated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005; 136:1658–68.

14. Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am. 2007; 19:487–98.

15. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a reviews of 63 cases. J Oral Maxillofac Surg. 2004; 62:527–34.

16. Chaudhry AN, Ruggiero SL. Osteonecrosis and bisphosphonates in oral and maxillofacial surgery. Oral Maxillofac Surg Clin North Am. 2007; 19:199–206.

17. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis)of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63:1567–75.

18. Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. Bisphosphonate-related osteonecrosis of the jaws: a singlecenter study of 101 patients. J Oral Maxillofac Surg. 2009; 67:850–5.

19. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009; 67:1904–13.

20. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102:433–41.

21. Tirelli G, Biasotto M, Chiandussi S, Dore F, de Nardi E, di Lenarda R, et al. Bisphosphonateassociated osteonecrosis of the jaws: the limits of a conservative approach. Head Neck. 2009; 31:1249–54.

22. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg. 2009; 67:943–50.

23. Arce K, Assael LA, Weissman JL, Makiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl):75–84.

24. Wutzl A, Biedermann E, Wanschitz F, Seemann R, Klug C, Baumann A, et al. Treatement results of bisphosphonate-related osteonecrosis of the jaws. Head Neck. 2008; 30:1224–30.

25. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl):85–95.

26. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl):96–106.

27. Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R, Lo Muzio L. Case 2. Osteoenecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol. 2006; 24:1475–7.

28. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos l, Antoniadis K, et al. Osteoenecrosis of thejaws due to bisphosphonate use. A review of 60 cases and treatmentproposals. Am J Otolaryngol. 2007; 28:158–63.

29. Nastro E, Musolino C, Allegra A, Oteri G, Cicciu ｀ M, Alonci A, et al. Bisphosphonateassociated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol. 2007; 117:181–7.

30. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial longterm extension(FLEX): a randomized trial. JAMA. 2006; 296:2927–38.

31. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. .;. American Society for Bone and Mineral Research. Bisphosphonateassociated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22:1479–91.

32. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg. 2009; 67(5 Suppl):35–43.

33. Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl):44–52.